US Appeals Court Revives False Claims Lawsuit Against Four Pharma Giants Over 340B Drug Pricing Violations
核心洞察
The US Court of Appeals for the Ninth Circuit ruled that AbbVie (搜索), AstraZeneca, Novartis, and Sanofi must face allegations of overcharging under the Section 340B Drug Pricing Program.
Adventist Health System/West (搜索) claims the companies knowingly charged prices exceeding statutory ceilings, leading to inflated Medicare and Medicaid reimbursements before 2019 policy changes.
The unanimous 3-0 decision overturns a previous district court dismissal and establishes that whistleblowers can pursue False Claims Act litigation on behalf of the government.
The US Court of Appeals for the Ninth Circuit has ruled that four major pharmaceutical companies—AbbVie (搜索), AstraZeneca, Novartis, and Sanofi—must defend against allegations that they defrauded federal healthcare programs through overcharging under the Section 340B Drug Pricing Program. The unanimous 3-0 decision in Pasadena, California, reverses a previous district court dismissal and allows the whistleblower lawsuit to proceed under the False Claims Act.
Court Ruling Establishes Legal Pathway for 340B Pricing Claims
Circuit Judge Roopali Desai wrote in the court's opinion: "Because Adventist asserts legally cognizable claims for relief under the FCA and has satisfied the necessary pleading requirements, we reverse and remand for further proceedings." The ruling establishes that while the 340B statute itself does not grant healthcare providers the ability to sue drug manufacturers directly for overcharges, the False Claims Act provides an alternative legal pathway for whistleblowers to pursue claims on behalf of the government.
The case was brought by Adventist Health System/West (搜索), a nonprofit healthcare provider based in Roseville, California, which operates more than 440 hospitals and clinics. The organization represents covered entities under the 340B program and filed the lawsuit seeking to recover losses on behalf of federal and state governments rather than pursuing personal damages.
Allegations of Systematic Overcharging
The lawsuit alleges that the pharmaceutical companies knowingly charged prices for drugs that exceeded the statutory ceiling—the maximum price manufacturers can charge covered entities, calculated as the average manufacturer price minus the required rebate. According to the complaint, these prolonged overcharges led Medicare and Medicaid to issue inflated reimbursements over a period of years.
The Section 340B program, established by Congress in 1992, requires pharmaceutical manufacturers to sell outpatient drugs at significantly discounted prices to eligible "covered entities," primarily safety-net hospitals and clinics serving deprived populations. In some cases, these discounted prices can drop as low as one cent, a mechanism commonly referred to as "penny pricing."
Industry Defense and Policy Context
The pharmaceutical companies had argued that Adventist had no right of action in this case, contending that disputes over 340B payments should be pursued under administrative procedures with federal and state governments. They claimed the healthcare provider was going beyond its position by effectively suing to enforce 340B regulations. This argument was previously supported by a California district court, which dismissed the complaint in March 2024.
The lawsuit points to a significant policy shift in 2019, when the U.S. Department of Health and Human Services began imposing significant civil penalties for violations of the 340B pricing rules. Adventist claims this policy change brought the alleged overcharging to a halt, suggesting the companies were aware their pricing practices violated program requirements.
Broader Implications for Healthcare Fraud Litigation
The decision comes as Section 340B has become a focal point for drug pricing-related litigation in the United States. The program has faced a series of challenges, including efforts to block an HHS pilot scheme seeking to implement a new rebate model that covered entities argue will cause harm and could force some facilities to close.
The False Claims Act allows private individuals, often referred to as whistleblowers, to file lawsuits on behalf of the government and share in any financial recovery. This provision has led to significant settlements in healthcare fraud cases, making it a powerful tool for addressing alleged misconduct in federal healthcare programs.
The appeals court has now sent the matter back to U.S. District Judge Dale Fischer in Los Angeles for further proceedings. Representatives for the four pharmaceutical companies and their legal teams declined to comment on the ruling, while attorneys for Adventist Health System/West (搜索) did not immediately respond to requests for comment.